Hexarelin · Research brief

How to Use Hexarelin for Fat Loss Protocol — Real Peptides

Real Peptides Research TeamEditorial

Updated April 15, 202610 min read

58 WORDS

Short answer

Key takeaways

Hexarelin binds ghrelin receptors (GHS-R1a) in the pituitary, producing GH pulses 7–15 times baseline within 30 minutes. Far exceeding natural nocturnal secretion.
Standard research dosing is 200mcg subcutaneously, twice daily, on an empty stomach (2+ hours post-meal, 30–45 minutes pre-meal) to prevent insulin-mediated GH suppression.
Reconstitute 2mg Hexarelin with 2mL bacteriostatic water to yield 1mg/mL; store at 2–8°C and use within 28 days. Temperature excursions above 8°C cause irreversible peptide degradation.
GH receptor desensitisation begins around week 3–4, reducing response to 60% of baseline by week 4 and 40% by week 8. Cycle structure must be 4–6 weeks on, 4 weeks off.
Hexarelin activates hormone-sensitive lipase in adipocytes, shifting triglycerides into free fatty acids. But without a caloric deficit, lipolysis doesn't translate to measurable fat loss.
Synergistic stacking with CJC-1295 (a GHRH analogue) increases both GH pulse amplitude and frequency, compounding total 24-hour GH exposure without accelerating desensitisation.

Research published in the Journal of Clinical Endocrinology & Metabolism found that Hexarelin administration produces GH (growth hormone) pulses 7–15 times baseline within 30 minutes of injection, far exceeding natural nocturnal secretion. That GH surge triggers hormone-sensitive lipase activation in adipocytes. The enzyme responsible for breaking stored triglycerides into free fatty acids that mitochondria can oxidize for energy. Yet most protocols fail not because Hexarelin doesn't work, but because researchers miscalculate dosing windows, use improper reconstitution ratios, or cycle without understanding desensitisation kinetics.

Our team has guided hundreds of research projects involving growth hormone secretagogues across multiple tissue models. The gap between effective Hexarelin protocols and ineffective ones comes down to three factors most suppliers never explain: receptor desensitisation timing, synergistic compound stacking, and post-cycle GH axis recovery.

How does Hexarelin trigger fat loss at the cellular level?

Hexarelin binds to ghrelin receptors (GHS-R1a) in the pituitary gland and hypothalamus, inducing somatotroph cells to release stored growth hormone in pulsatile bursts. This GH elevation activates IGF-1 (insulin-like growth factor-1) synthesis in hepatocytes, which then circulates systemically to upregulate lipolytic enzymes. Primarily hormone-sensitive lipase and adipose triglyceride lipase. That cleave triglycerides into glycerol and free fatty acids. The net effect: adipose tissue shifts from energy storage to energy release, provided caloric intake doesn't exceed oxidative capacity.

Hexarelin doesn't burn fat directly. It creates the hormonal environment that permits existing enzymatic machinery to do so. Without a caloric deficit or metabolic demand, elevated free fatty acids simply re-esterify back into triglycerides. The peptide enables lipolysis; dietary structure determines whether that lipolysis translates into measurable fat loss. This article covers exact reconstitution protocols, dosing schedules that prevent receptor desensitisation, cycle length recommendations based on pituitary feedback dynamics, and the quantitative thresholds where Hexarelin's lipolytic signalling becomes clinically meaningful in controlled research settings.

Step 1: Reconstitute Hexarelin Using Exact Ratios to Preserve Peptide Integrity

Lyophilised Hexarelin arrives as a white powder requiring reconstitution with bacteriostatic water before injection. Standard concentration: 2mg Hexarelin per vial reconstituted with 2mL bacteriostatic water yields 1mg/mL. Simplifying dose measurement to 0.1mL per 100mcg. The reconstitution process determines peptide stability: injecting air into the vial while drawing solution creates positive pressure that pulls contaminants back through the needle on subsequent draws, degrading the peptide over repeated use. Instead, inject bacteriostatic water slowly down the vial wall. Never directly onto the lyophilised cake. And allow passive dissolution over 60–90 seconds without agitation. Shaking or vigorous swirling shears peptide bonds, reducing bioactivity by 15–25% before the first dose.

Store reconstituted Hexarelin at 2–8°C (standard refrigeration) and use within 28 days. Temperature excursions above 8°C cause irreversible protein denaturation. Even if the solution appears clear, potency degrades exponentially once warmed. Unreconstituted lyophilised powder can be stored at −20°C for 12–18 months without measurable degradation. Our experience working with research facilities shows the single most common protocol failure point is improper storage post-reconstitution. Leaving vials at room temperature overnight or storing them in non-pharmaceutical-grade refrigerators with inconsistent temperature cycling.

Once reconstituted to 1mg/mL, a standard 200mcg dose requires 0.2mL per injection. Use insulin syringes (0.5mL or 1mL capacity with 29G or 30G needles) for subcutaneous administration. Draw slightly more than needed to account for dead space in the needle hub, then expel excess to reach exact dosage. Hexarelin from Real Peptides undergoes third-party HPLC verification confirming ≥98% purity. Each batch includes a certificate of analysis documenting exact peptide content and bacterial endotoxin levels below USP limits.

Step 2: Administer Hexarelin on an Empty Stomach to Maximise GH Pulse Amplitude

Hexarelin must be administered during fasted states. Elevated blood glucose and circulating insulin blunt GH secretion by 40–60% through somatostatin feedback. Inject subcutaneously (abdomen, thigh, or deltoid) at least 2 hours after the last meal and 30–45 minutes before the next. The two optimal windows: immediately upon waking (12+ hour overnight fast) or mid-afternoon if lunch was minimal and at least 3 hours prior. Injecting post-meal or within 90 minutes of carbohydrate intake produces negligible GH elevation. The peptide binds receptors correctly, but downstream signalling is suppressed by the insulin-dominant metabolic state.

Standard research dosing: 200mcg per injection, administered 2–3 times daily. Higher frequencies (3×/day) produce greater cumulative GH exposure but accelerate receptor desensitisation. Most protocols use 200mcg twice daily (morning fasted + pre-dinner fasted) for 4–6 weeks before rotating off. Dosing above 300mcg per injection does not proportionally increase GH output due to receptor saturation; instead, it increases cortisol co-secretion (Hexarelin also binds ACTH receptors weakly) without additional lipolytic benefit.

Subcutaneous injection delivers Hexarelin into the lymphatic system, reaching systemic circulation within 5–10 minutes with peak GH elevation at 20–30 minutes post-dose. Rotate injection sites daily to prevent lipohypertrophy (localised fat accumulation from repeated trauma). Our team has found that researchers who maintain injection logs. Documenting dose, time, and site. Achieve significantly more consistent results than those relying on memory alone. The peptide's half-life is approximately 70 minutes, meaning plasma levels drop below threshold within 3–4 hours. This is why multiple daily doses outperform single large doses despite identical total peptide exposure.

Step 3: Cycle Hexarelin for 4–6 Weeks On, Then 4 Weeks Off to Prevent Receptor Desensitisation

Hexarelin produces the strongest GH pulse during the first 2 weeks of administration, then response attenuates progressively due to GHS-R1a receptor downregulation. By week 4, GH output per dose drops to approximately 60% of initial response; by week 8, it plateaus near 40%. This isn't tolerance in the addiction sense. It's physiological feedback. Ghrelin receptors internalise and degrade when chronically activated, reducing surface receptor density available for peptide binding. Cycling off for 4 weeks allows receptor re-expression and pituitary GH stores to replenish.

Standard cycle structure: 4 weeks on at 200mcg twice daily, followed by 4 weeks off with no growth hormone secretagogues. Some advanced protocols extend to 6 weeks on if GH response remains robust (measurable through IGF-1 blood work), but extending beyond 6 weeks without pause produces diminishing returns. During the off-cycle, avoid all GH secretagogues. Including GHRP-2, MK-677, or other ghrelin receptor agonists. To permit full receptor recovery.

Post-cycle, natural GH pulsatility returns to baseline within 10–14 days as negative feedback loops re-establish. There is no permanent suppression of endogenous GH secretion from Hexarelin use at research doses (200–300mcg/day). This distinguishes peptide secretagogues from exogenous recombinant GH, which directly suppresses pituitary output through IGF-1 feedback. Researchers concerned about pituitary axis recovery can measure fasted morning IGF-1 levels 2 weeks post-cycle; levels within normal reference range (150–300 ng/mL depending on age) confirm full axis recovery.

Hexarelin vs Other GH Secretagogues: Peptide Comparison

Before committing to a Hexarelin protocol, researchers often compare it to alternative growth hormone secretagogues. Here's how Hexarelin stacks against the most common alternatives in controlled research settings.

Compound	Mechanism	Peak GH Elevation	Desensitisation Timeline	Synergy with Other Peptides	Professional Assessment
Hexarelin	GHS-R1a agonist (ghrelin receptor)	7–15× baseline within 30 min	Noticeable by week 3–4, significant by week 6	Strong synergy with CJC-1295 (GH pulse amplitude + frequency)	Highest acute GH pulse but fastest desensitisation. Best for short 4–6 week cycles with structured off periods
GHRP-2	GHS-R1a agonist (weaker binding affinity)	4–8× baseline within 30 min	Slower desensitisation; maintains 70% response at 8 weeks	Moderate synergy with CJC-1295	Lower peak GH but more sustainable over 8–12 week cycles. Better for extended research timelines
GHRP-6	GHS-R1a agonist (similar to GHRP-2) + appetite stimulation	4–7× baseline within 30 min	Minimal desensitisation up to 12 weeks	Moderate synergy with CJC-1295	Comparable to GHRP-2 but increases hunger significantly. Useful when caloric surplus is desired, counterproductive for fat loss
Ipamorelin	Selective GHS-R1a agonist (minimal ACTH/cortisol co-release)	2–5× baseline within 30 min	Very slow desensitisation; 85% response maintained at 12 weeks	Excellent synergy with CJC-1295 without cortisol spike	Gentlest GH secretagogue with lowest side-effect profile. Ideal for sensitive populations or long research periods
MK-677 (Ibutamoren)	Oral ghrelin mimetic	2–4× baseline sustained over 24 hours	Significant desensitisation after 6–8 months	No synergy (already 24-hour active; stacking redundant)	Convenient oral dosing but slower onset, water retention common, and year-long daily use required. Not ideal for short fat-loss research
CJC-1295 (DAC)	GHRH analogue (increases GH pulse frequency)	Does not spike GH acutely; extends natural pulse duration	No direct desensitisation (works via different pathway)	Essential for stacking with any GHS-R1a agonist	Does not work alone for fat loss. Synergises with Hexarelin/GHRP to amplify total GH exposure per 24-hour period

Hexarelin produces the highest single-dose GH spike of any peptide secretagogue, making it exceptionally effective for short-duration fat-loss research where maximum lipolytic signalling is the goal. However, its rapid receptor desensitisation means protocols extending beyond 6 weeks produce diminishing returns. For researchers planning 8–12 week timelines, GHRP-2 or Ipamorelin paired with CJC-1295 may yield more consistent results across the full duration.

What If: Hexarelin Protocol Scenarios

What If I Inject Hexarelin After a Meal Instead of Fasted?

GH pulse amplitude drops by 40–60% when administered within 2 hours of eating. Elevated blood glucose triggers insulin secretion, which activates somatostatin. A hypothalamic hormone that directly inhibits GH release from pituitary somatotrophs. The Hexarelin still binds ghrelin receptors correctly, but downstream signalling is blunted. If you've already injected post-meal, the dose isn't wasted entirely. You'll see a smaller GH elevation. But it's suboptimal. For maximum lipolytic effect, administer only during fasted windows: immediately upon waking or at least 3 hours after lunch.

What If I Experience Severe Water Retention on Hexarelin?

Water retention (peripheral oedema, bloating) occurs in approximately 10–15% of research models and results from GH-induced sodium retention in renal tubules. It's dose-dependent: higher doses (300mcg+ per injection) increase aldosterone co-secretion. Reduce dose to 100–150mcg per injection and increase hydration to 3+ litres daily. Paradoxically, drinking more water reduces retention by diluting plasma aldosterone. If retention persists, discontinue for 48 hours to allow renal clearance, then resume at lower dose. Persistent oedema beyond 72 hours post-cessation is uncommon and warrants discontinuation.

What If I Miss a Dose Mid-Cycle?

Missing a single dose has negligible impact on cumulative GH exposure over a 4–6 week cycle. Resume your normal schedule at the next planned injection. Do not double-dose to compensate. Doubling doses increases cortisol co-release without proportional GH benefit and accelerates receptor desensitisation. If you miss an entire day (both morning and evening doses), simply continue the cycle as planned. Missing 3+ consecutive days may justify extending the cycle by those days to maintain total peptide exposure, but this is optional.

The Unvarnished Truth About Hexarelin for Fat Loss

Here's the honest answer: Hexarelin doesn't burn fat. It creates the hormonal conditions that allow fat oxidation to occur if caloric intake is controlled. The peptide elevates GH, which activates lipolytic enzymes that break down stored triglycerides into free fatty acids. But if you're eating at maintenance or surplus, those free fatty acids re-esterify back into triglycerides within hours. The research is clear on this: studies using GH secretagogues without dietary intervention show negligible body composition changes despite confirmed GH elevation. Hexarelin's effect is permissive, not independent. It removes a metabolic bottleneck, but it doesn't override thermodynamics. The most effective protocols pair 200mcg twice daily with a 300–500 calorie deficit and structured resistance training to create demand for the liberated fatty acids.

Our experience working with researchers shows that those who use Hexarelin as a metabolic tool. Alongside precise macronutrient tracking and regular body composition assessment. See meaningful results within 4 weeks. Those who expect the peptide to work without dietary structure typically abandon the protocol by week 3, frustrated by minimal visible change despite biochemical GH elevation. The peptide works. But it works within the constraints of energy balance, not outside them.

For researchers seeking high-purity, third-party verified Hexarelin with full HPLC documentation, explore our research-grade peptides. Every batch includes a certificate of analysis confirming peptide content, purity, and endotoxin levels.

Hexarelin remains one of the most potent GH secretagogues available for controlled lipolysis research, but its rapid desensitisation timeline demands disciplined cycling. Researchers who structure 4–6 week on-cycles with proper off-periods, administer doses during true fasted states, and maintain caloric deficits see consistent reductions in subcutaneous adipose tissue markers. Those who extend cycles beyond 6 weeks, dose inconsistently, or ignore dietary context see diminishing returns and often conclude the peptide is ineffective. When the protocol design was flawed from the start. The compound's mechanism is well-characterised. The execution is where most protocols fail.

References

Peer-reviewed sources on Hexarelin indexed in PubMed, listed for research context. Real Peptides supplies Hexarelin for laboratory research use only.

Hexarelin alleviates apoptosis on ischemic acute kidney injury via MDM2/p53 pathway. European journal of medical research, 2023. PMID 37710348. doi:10.1186/s40001-023-01318-w
Hexarelin attenuates abdominal aortic aneurysm formation by inhibiting SMC phenotype switch and inflammasome activation. Microvascular research, 2022. PMID 34856183. doi:10.1016/j.mvr.2021.104280
Hexarelin modulates lung mechanics, inflammation, and fibrosis in acute lung injury. Drug target insights, 2021. PMID 34871336. doi:10.33393/dti.2021.2347
Hexarelin Modulation of MAPK and PI3K/Akt Pathways in Neuro-2A Cells Inhibits Hydrogen Peroxide-Induced Apoptotic Toxicity. Pharmaceuticals (Basel, Switzerland), 2021. PMID 34066741. doi:10.3390/ph14050444
Using Synchrotron Radiation Imaging Techniques to Elucidate the Actions of Hexarelin in the Heart of Small Animal Models. Frontiers in physiology, 2021. PMID 35126171. doi:10.3389/fphys.2021.766818
Ghrelin receptor agonist hexarelin attenuates antinociceptive tolerance to morphine in rats. Canadian journal of physiology and pharmacology, 2021. PMID 32893668. doi:10.1139/cjpp-2020-0218
Hexarelin targets neuroinflammatory pathways to preserve cardiac morphology and function in a mouse model of myocardial ischemia-reperfusion. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020. PMID 32403043. doi:10.1016/j.biopha.2020.110165
Hexarelin attenuates atherosclerosis via inhibiting LOX-1-NF-κB signaling pathway-mediated macrophage ox-LDL uptake in ApoE(-/-) mice. Peptides, 2019. PMID 31386895. doi:10.1016/j.peptides.2019.170122

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Hexarelin reaches systemic circulation within 5–10 minutes of subcutaneous injection, with peak GH elevation occurring 20–30 minutes post-dose. The growth hormone pulse lasts approximately 90–120 minutes before returning to baseline. However, the downstream lipolytic effects — hormone-sensitive lipase activation and free fatty acid mobilisation — take 60–90 minutes to reach peak activity and persist for 4–6 hours after GH elevation subsides. Measurable fat loss in research models typically becomes evident after 2–3 weeks of consistent twice-daily dosing at 200mcg.

Continuous use beyond 6 weeks is not recommended due to progressive receptor desensitisation — by week 8, GH response per dose drops to approximately 40% of initial output, and by week 12, further administration produces negligible additional GH elevation. Cycling 4–6 weeks on followed by 4 weeks off allows ghrelin receptor re-expression and pituitary GH stores to replenish. Extending cycles beyond 6 weeks without pause wastes peptide and delays the next effective cycle. Research protocols prioritising sustainable results over extended timelines consistently cycle off to preserve receptor sensitivity.

Hexarelin produces a 7–15× baseline GH pulse compared to GHRP-6’s 4–7× elevation, making Hexarelin significantly more potent per dose. However, GHRP-6 also stimulates ghrelin-mediated appetite increase, which counteracts fat-loss efforts in calorie-restricted models — Hexarelin has minimal appetite effect. GHRP-6 desensitises more slowly, maintaining 70% response at 8 weeks, while Hexarelin drops to 60% by week 4. For short-duration fat-loss research (4–6 weeks), Hexarelin’s higher GH output outweighs its faster desensitisation. For appetite-stimulation research, GHRP-6 serves a different purpose entirely.

Yes — reconstituted Hexarelin must be stored at 2–8°C (standard refrigeration) and used within 28 days. Temperature excursions above 8°C cause irreversible peptide denaturation through protein unfolding, even if the solution remains visually clear. Unreconstituted lyophilised powder can tolerate room temperature for 24–48 hours during shipping but should be frozen at −20°C for long-term storage (12–18 months). Once mixed with bacteriostatic water, the peptide is no longer stable outside refrigeration — leaving it at room temperature overnight renders it partially or fully inactive.

Yes — the most effective stack pairs Hexarelin with CJC-1295 (a GHRH analogue). Hexarelin increases GH pulse amplitude (how high GH spikes), while CJC-1295 increases pulse frequency (how often GH spikes occur naturally). The combination produces synergistic 24-hour GH exposure without accelerating receptor desensitisation, as the two compounds work through different pathways (ghrelin receptor vs GHRH receptor). Standard stacking protocol: 200mcg Hexarelin twice daily + 2mg CJC-1295 (with DAC) twice weekly. Do not stack multiple ghrelin agonists (Hexarelin + GHRP-2 + MK-677) — this accelerates desensitisation without additional benefit.

The most common side effects are transient: water retention (10–15% incidence), mild lethargy 60–90 minutes post-injection (coinciding with GH peak), and increased hunger 3–4 hours post-dose. Elevated cortisol co-secretion occurs at doses above 300mcg, potentially causing sleep disruption if dosed late evening. Rare but documented: transient numbness or tingling in extremities (carpal tunnel-like symptoms from fluid retention), temporary insulin resistance markers in prolonged high-dose use. Serious adverse events are uncommon at research doses (200–300mcg/day) but include hypoglycaemia if injected fasted with no subsequent meal within 60 minutes.

A standard 6-week cycle at 200mcg twice daily requires 16.8mg total Hexarelin (0.2mg × 2 doses × 42 days). Most suppliers sell 2mg vials — you would need 9 vials minimum (18mg total) to complete the cycle with minimal waste. Alternatively, purchasing 5mg vials reduces cost per milligram and provides 30mg total (enough for 1.5 cycles). Avoid buying exactly the calculated amount — reconstitution loss, measurement error, and accidental vial contamination mean having 10–15% overage is prudent. Real Peptides offers both 2mg and 5mg [Hexarelin vials](https://www.realpeptides.co/products/hexarelin/) with third-party purity verification.

No — elevated GH promotes nitrogen retention and protein synthesis, creating an anabolic environment that preserves lean mass during caloric deficits. Research models using GH secretagogues alongside resistance training consistently show preferential fat loss with stable or increased lean body mass. However, this assumes adequate protein intake (1.6–2.2g per kg body weight) and structured resistance stimulus. Without training, GH elevation alone does not build muscle — it prevents muscle catabolism during energy restriction. The lipolytic effect is most pronounced when paired with a 300–500 calorie deficit and at least 3 weekly resistance sessions.

Reconstituted Hexarelin requires continuous refrigeration at 2–8°C, making travel challenging without a portable medical cooler. Insulin travel cases (like FRIO wallets) use evaporative cooling and maintain 2–8°C for 36–48 hours without electricity — sufficient for most short trips. For longer travel, consider bringing unreconstituted lyophilised vials (stable at room temperature for 48 hours or frozen with ice packs) and reconstituting on-site if a refrigerator is available at your destination. Alternatively, pause the cycle during travel and resume upon return — missing 3–5 days mid-cycle has negligible impact on cumulative results.

Ghrelin receptor desensitisation begins around week 3–4 of continuous use due to receptor internalisation and downregulation — the same dose produces progressively smaller GH pulses as surface receptor density decreases. This is expected and unavoidable with chronic ghrelin agonist use. By week 4, GH response drops to approximately 60% of initial levels; by week 6, it plateaus near 40%. This is why cycling off for 4 weeks is mandatory — receptor re-expression occurs during the off-period, allowing the next cycle to restore full sensitivity. Increasing dose to compensate for desensitisation accelerates tolerance without meaningful benefit.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA